In their analysis, PCSK9 inhibitor genetic targets causally increased the risk of AD, though the authors admit that the inhibitors tested (evolocumab and alirocumab) are not able to cross the BBB and access the brain, so genetics may not be the most informative method to answer their question [242]. Here, PCSK9 is linked to Alzheimer disease.